Eczema Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

For all participants:

• Adults between 18 and 65 years old (inclusive) at the time of giving consent
• People who are willing and able to give their informed consent before any study procedures begin
• People who are willing to follow all study procedures and are available for the full duration of the study

For people with chronic hand eczema (CHE) only:

• People who have had chronic hand eczema for at least 6 months before the screening visit
• People whose hand eczema is rated as moderate to severe (based on a doctor's assessment score) at both the screening visit and Day 1
• People whose hand eczema covers at least a small defined area of the palm surface of the hands at both the screening visit and Day 1
• People whose hand eczema fits into one of several recognised types, such as atopic hand eczema, irritant contact eczema, hyperkeratotic (thickened skin) eczema, blister-type eczema, allergic contact eczema, or a form with no identified cause — as assessed on Day 1

For people with atopic dermatitis (AD) only:

• People with a clinically confirmed diagnosis of active atopic dermatitis, based on established medical criteria
• People who have had atopic dermatitis for at least 6 months and have had no significant flare-ups for at least 4 weeks before the screening visit
• People whose atopic dermatitis is rated as moderate to severe (based on a doctor's assessment score) at both the screening visit and Day 1
• People whose atopic dermatitis covers at least a defined area of the body at both the screening visit and Day 1
• People who have an atopic dermatitis patch covering a defined minimum area on the forearm at both the screening visit and Day 1

For healthy volunteers only:

• People who are in good general health, based on the study doctor's assessment of medical history and a physical examination

Who may not be able to join:

For all participants:

• People with a history of, or current, skin disease or skin condition that the study doctor believes would interfere with assessments
• People who have taken antibiotic tablets, capsules, or other whole-body antibiotic treatments within 2 weeks before Day 1
• People who have used antibiotic creams or ointments applied to the skin within 1 week before Day 1
• People who have used skin products containing urea or salicylic acid within 1 week before Day 1
• People who have received a biological medicine (approved or experimental) within 12 weeks or 5 half-lives of the drug (whichever is longer) before Day 1
• People who are currently using, or have used within 4 weeks before Day 1, a non-biological experimental medicine or device
• People who have had excessive sun exposure, are planning a trip to a sunny climate, or have used tanning booths within 4 weeks before Day 1
• People who are pregnant or planning to become pregnant during the study

For people with chronic hand eczema (CHE) only:

• People whose hand eczema on the hands and/or wrists is currently infected
• People whose hand eczema is suspected or confirmed to be caused by a protein contact reaction (confirm with trial site)
• People who have used the antihistamine doxepin within 1 week before Day 1
• People who have used the antihistamines hydroxyzine or diphenhydramine within 1 week before Day 1
• People who have used any medicated skin treatment that could affect hand eczema within 1 week before Day 1 — including steroid creams, retinoid creams, crisaborole, calcineurin inhibitors, tar products, antimicrobials, certain medical devices, or bleach baths
• People who have used systemic retinoid medicines (such as alitretinoin, isotretinoin, or acitretin) within 4 weeks before Day 1, or who have not fully recovered from their side effects
• People who have used whole-body (systemic) treatments that could affect hand eczema within 4 weeks before Day 1 — such as calcineurin inhibitors, methotrexate, cyclosporin, hydroxyurea, azathioprine, or steroid tablets or injections (note: steroid nasal sprays, eye or ear drops with steroids, and inhaled steroids for stable conditions are permitted)
• People who have used the biological medicine dupilumab within 12 weeks before Day 1
• People who have received UV-B light therapy (including tanning beds) or excimer laser treatment within 4 weeks before Day 1
• People who have had PUVA (a specific type of light therapy combining a medicine and UV-A light) within 4 weeks before Day 1

For people with atopic dermatitis (AD) only:

• People whose atopic dermatitis is currently infected
• People who have atopic dermatitis patches on the hands and/or feet at the screening visit or Day 1
• People who have received intravenous immunoglobulin (IVIg) therapy within 12 weeks before Day 1
• People who have used doxepin within 1 week before Day 1
• People who have used hydroxyzine or diphenhydramine within 1 week before Day 1
• People who have used any medicated skin treatment that could affect atopic dermatitis within 1 week before Day 1 — including steroid creams, crisaborole, calcineurin inhibitors, ruxolitinib, tar products, antimicrobials, certain medical devices, or bleach baths
• People who have used whole-body (systemic) treatments that could affect atopic dermatitis within 4 weeks before Day 1 — including retinoids, calcineurin inhibitors, methotrexate, cyclosporine, hydroxyurea, azathioprine, steroid tablets or injections, baricitinib, upadacitinib, or abrocitinib (note: steroid nasal sprays, inhaled steroids, and steroid eye or ear drops are permitted)
• People who have used the biological medicine dupilumab within 12 weeks before Day 1
• People who have received UV-B light therapy (including tanning beds) or excimer laser treatment within 4 weeks before Day 1
• People who have had PUVA treatment within 4 weeks before Day 1
• People who have used the biological medicine tralokinumab within 12 weeks before Day 1

For healthy volunteers only:

• People with a history of atopic dermatitis, allergic rhinitis (hay fever), or asthma

Important: Always verify eligibility with the trial site directly before applying.